TD Cowen Rates Nuvalent (NUVL) hold, $124 Price Target

TD Cowen analyst Marc Frahm lowers Nuvalent to hold, setting a $124 price target, a 0.61% upside from the current price.

By TradeTexts Research Desk · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 15, 2026, 2:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen rated Nuvalent, Inc. ($NUVL) "hold" with a $124 price target on June 10, 2026.

Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).

NUVL Nuvalent, Inc.

$123.43 +22.40% year to date

Daily close · Jun 18, 2026

Key Points

TD Cowen analyst Marc Frahm lowered Nuvalent, Inc.'s rating to hold with a $124 price target on June 10, 2026.
TD Cowen's $124 price target implies 0.61% upside from Nuvalent, Inc.'s ($NUVL) current $123.25 share price.
Nuvalent's stock traded near $123.25 on the NasdaqGS, with a market cap of about $9.75 billion, a forward P/E of -29.83, and a beta of 1.153.
Insider transactions included sales by the CEO and Chief Development Officer, while several funds like JPMorgan Chase & Co increased their shares.

Get $NUVL trade alerts by text

We text you when insiders, Congress or big funds trade $NUVL. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Nuvalent, Inc. alert may contain errors. Disclosures

TD Cowen has downgraded Nuvalent, Inc. (NasdaqGS: NUVL) to a hold rating, setting a price target of $124. This move by analyst Marc Frahm was announced on June 10, 2026. Shares of Nuvalent recently traded around $123.25.

Other Institutional Activity in Nuvalent

Several institutional investors have also been active in Nuvalent. Deerfield Management Company maintained its position with 17.2 million shares valued at approximately $1.77 billion. FMR LLC reduced its holdings by about 1.58 million shares, ending with 9.27 million shares worth $950.2 million. Paradigm Biocapital Advisors LP added 55,000 shares, bringing their total to 5.32 million shares valued at $545.5 million. BlackRock, Inc. increased its stake slightly by 19,524 shares to 4.82 million shares, valued at $494.3 million. Meanwhile, JPMorgan Chase & Co boosted its position by 883,098 shares, reaching a total of 3.09 million shares worth nearly $298.7 million.

Nuvalent, Inc. Stock Snapshot

Nuvalent's stock is trading near $123.25 with a market capitalization of approximately $9.75 billion. The company has a forward P/E ratio of -29.83, indicating it's not currently profitable. Its beta is 1.153, suggesting moderate volatility. Over the past 52 weeks, the stock has ranged from $71.13 to $123.62. The 50-day moving average is $104.10, while the 200-day moving average sits at $98.73. Nuvalent has a strong current ratio of 16.14 and a quick ratio of 15.89.

12-month forecast

$NUVL price target

Nuvalent, Inc. daily closes and this analyst's $124 target. Not advice.

Recent Earnings

Nuvalent's financials show a net margin of 0% and a return on equity of -41.19%. The company reported an EPS of -$6.06. The next earnings release is scheduled for August 6, 2026.

Insider Buying and Selling at Nuvalent, Inc.

Recent insider transactions at Nuvalent include sales by Chief Development Officer Darlene Noci, who sold 20,000 shares on June 9, 2026, at an average price of $122.81. This sale was planned under a Rule 10b5-1 trading plan. President and CEO Dr. James R. Porter also sold 30,000 shares on June 8, 2026, at an average price of $88.53, also under a planned trading arrangement.

Analysts Set New Price Targets

On June 10, 2026, several firms, including TD Cowen, Barclays, and UBS, downgraded Nuvalent to a hold rating, each setting a price target of $124. The consensus among analysts is a hold recommendation, with a mean price target of $128.13 based on 16 opinions.

About Nuvalent, Inc.

Nuvalent, Inc., based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company's leading candidates include Zidesamtinib for ROS1-positive non-small cell lung cancer, Neladalkib for ALK-positive cancers, and NVL-330 targeting HER2-driven tumors. Dr. James R. Porter serves as CEO, guiding the company's efforts to address treatment resistance and adverse events associated with existing therapies.

Bottom Line

TD Cowen's recent downgrade of Nuvalent to a hold rating reflects a cautious stance amidst the company's ongoing clinical developments. With a market cap nearing $10 billion, Nuvalent remains a significant player in the biotech space, though its lack of profitability is notable. As a clinical-stage firm, its future performance will largely depend on the success of its pipeline therapies.